Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...
Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...
RFK Jr. is declaring war on chronic illness, which, if he succeeds, will not only make us healthier but will also cut down ...
Robert F. Kennedy Jr., if confirmed as HHS secretary, could help food-as-medicine startups expand with wider government ...
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Blair County's Chief Clerk and County Administrator, Sherry Socie, has resigned, again.
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...